Raptors sign centre Poetl to 4-year extension worth reported $104M US
Financial details were not disclosed, but multiple outlets reported the deal is worth $104 million US over four years.
The 29-year-old from Austria averaged a career-high 14.5 points and 9.6 rebounds, along with 1.2 blocks and 1.2 steals in 57 regular-season games for the Raptors last season.
He also shot 62.7 per cent from the field, ranking fifth in the NBA among qualified players.
Poeltl, a first-round pick (ninth overall) by the Raptors in the 2016 NBA draft, was traded to the San Antonio Spurs with DeMar DeRozan in the Kawhi Leonard deal back in 2018.
The seven-foot, 245-pound Poeltl has averaged 8.9 points, 7.0 rebounds and 1.3 blocks in 595 career games.
'I want to be a Raptor for life'
"Toronto has always felt like home for me — I want to be a Raptor for life," Poeltl said in a release. "Thanks to [general manager Bobby Webster] and team ownership for believing in me, and to the fans for their amazing support.
"We have a young core that's full of potential and I believe we're ready to take the next step. I can't wait to get together back on the Scotiabank Arena court."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 minutes ago
- Globe and Mail
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast
Tuesday, July 8, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), AstraZeneca PLC (AZN) and Comcast Corp. (CMCSA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Mixed at Start of Prime Day, Awaiting Trade Deals Today's Featured Research Reports T-Mobile's shares have outperformed the Zacks Wireless National industry over the past year (+34.5% vs. +30.7%). The company is benefiting from industry-leading postpaid customer growth with a record-low churn rate. Its acquisition strategy has significantly strengthened its position in the wireless industry over the past few years. TMUS' 2.5 GHz 5G spectrum delivers superfast speeds and extensive coverage with signals that go through walls and trees. This boosts its competitive edge against companies that provide 5G networks controlled by the mmWave spectrum. However, owing to the stock's premium valuation, we believe investors should remain cautious as macroeconomic factors, market saturation, or economic downturns can significantly impact overvalued stocks like TMUS. Fierce competition is straining profitability. To lure customers from competitors, T-Mobile has launched several low-priced service plans for consumers. This has put pressure on profits. (You can read the full research report on T-Mobile here >>>) Shares of AstraZeneca have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+7.7% vs. -2%). The company's key drugs like Lynparza, Tagrisso, Imfinzi and Fasenra should keep driving revenues. Its pipeline is strong, with pivotal late- and mid-stage pipeline data readouts lined up. AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline. AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology sales and slowing sales of rare disease drugs are expected to hurt the top line in 2025. Estimates have declined slightly ahead of the Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters. (You can read the full research report on AstraZeneca here >>>) Comcast's shares have underperformed the Zacks Cable Television industry over the year-to-date period (-3.1% vs. +4.2%). The company has been persistently suffering from video-subscriber attrition due to cord-cutting. Broadband prospects are suffering from increased competition from fixed wireless and fiber businesses. Theme Parks revenues declined due to lower revenues at domestic theme parks, driven by lower guest attendance, including the impact of the Hollywood wildfires. A leveraged balance sheet is a major concern for Comcast. Nevertheless, steady growth in Content & Experiences revenues driven by steady performances by Studios and Media segments is positive. Its streaming service, Peacock, has been a key catalyst in driving broadband sales. Decreasing programming & production costs bode well for CMCSA's profitability. Strong free cash flow generation ability is noteworthy. (You can read the full research report on Comcast here >>>) Other noteworthy reports we are featuring today include Entergy Corp. (ETR), Align Technology, Inc. (ALGN) and Universal Health Services, Inc. (UHS). Mark Vickery Senior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read T-Mobile (TMUS) Rides on Solid 5G Expansion, Strong Cash Flow Key Drugs Aid AstraZeneca (AZN) Sales, Pipeline Strong Domestic Wireless Subscriber Gain Benefits Comcast (CMCSA) Featured Reports Investments Aid ETR Corporation (ETR) Amid Poor Solvency Per the Zacks analyst, ETR Corp. makes disciplined investment to maintain and upgrade the reliability of its electric utility systems. Yet its poor financial ratios indicate weak solvency position. Align (ALGN) Rides on Growing Invisalign Volume, Innovation The Zacks analyst is optimistic about Align's strong market rollout of several Invisalign products globally. The company's focused efforts to expand portfolio aids growth. Rising Admissions Aid Universal Health (UHS), High Costs Ail Per the Zacks analyst, Universal Health's continued growth in admissions at its acute care facilities will boost its top line. However, escalating expenses remain a concern for the company. Strong SMB clientele Aids BILL Holdings' (BILL) Prospects Per the Zacks analyst, BILL is benefiting from an expanding small and medium business (SMB) clientele, as well as a diversified business model. Expanding Customer Base & Smart Investment Aid ONE Gas (OGS) Per the Zacks analyst, ONE Gas is set to benefit from capital expenditure plan and extension of services to new areas. Steady demand from residential customers boosts its performance. Business Growth Plans Aid Boise Cascade (BCC), Macro Risks Ail Per the Zacks analyst, Boise Cascade is gaining from accretive business growth strategies, while ensuring shareholder value. However, housing market softness and macro risks hurt prospects. Sarepta (SRPT) Growth Outlook Dimmed by Elevidys Concerns Though Sarepta's pipeline of LGMD therapies holds potential, the Zacks analyst is concerned with two Elevidys-linked deaths and their impact on topline growth. New Upgrades Loan Growth & Strong Liquidity Supports SouthState (SSB) Per the Zacks analyst, SouthState's expanding loan balance and solid non-interest income will aid top-line growth. Its strong liquidity position enables sustainable capital distributions. SkyWest (SKYW) Benefits From Improving Air-Travel Demand The Zacks Analyst is impressed with the fact that increased air-travel demand is helping SkyWest carry more passengers and witness more revenues. TreeHouse Foods (THS) Drives Growth with Supply Chain Wins Per the Zacks analyst, TreeHouse Foods accelerates margin expansion with supply chain efficiencies, streamlined operations, and a focused portfolio in high-growth private label categories. New Downgrades Expected Decline in Sales & High Capex to Ail Magna (MGA) Per the Zacks analyst, Magna's 2025 revenues are expected to decline due to lower light vehicle production in North America. High capex requirement is likely to strain near-term cash flows. Trucking Costs & Oil Price Swings to Ail Vista Energy (VIST) Per the Zacks analyst, Vista Energy's heavy reliance on trucking for transporting production and its exposure to volatile international oil prices are expected to weigh on its profitability. Weak Digital Sales Hurts Bath & Body Works' (BBWI) Growth Per the Zacks analyst, despite favorable foot traffic, BBWI's digital softness in first quarter suggests cracks in its e-commerce strategy that could weigh on future performance. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Entergy Corporation (ETR): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report T-Mobile US, Inc. (TMUS): Free Stock Analysis Report
CBC
17 minutes ago
- CBC
2025 Canada Cup Women's Softball: SoCal Sting vs Canada
Watch the SoCal Sting and Team Canada go head-to-head from the 2025 Canada Cup at Softball City in Surrey, B.C.
CBC
20 minutes ago
- CBC
Yukon hockey phenom to announce NCAA plans today
Social Sharing Gavin McKenna is almost certainly NHL-bound, but first, he's making a stop in the NCAA. The 17-year-old Yukoner is expected to announce today he's committing to the Penn State Nittany Lions, to play collegiate hockey. McKenna will make the announcement on ESPN's SportsCenter at 3 p.m. YT today. CBC North has confirmed he'll be joining Penn State. Widely expected to be the No. 1 overall pick in next year's NHL draft, McKenna leaves the Western Hockey League's Medicine Hat Tigers to join the United States college ranks. McKenna had 41 goals and 88 assists in 56 regular-season games last season and helped Medicine Hat win its first WHL title since 2007 and reach the Memorial Cup final. In June, the six-foot winger became the third-youngest Canadian Hockey League player of the year, only Sidney Crosby and John Tavares were younger. The NCAA lifted a long-standing ban in November, allowing CHL players to compete at U.S. colleges starting next season.
